Panacea Biotec

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE922B01023
  • NSEID: PANACEABIO
  • BSEID: 531349
INR
336.25
-17.05 (-4.83%)
BSENSE

Nov 20

BSE+NSE Vol: 1.39 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 622974,
    "name": "Panacea Biotec",
    "stock_name": "Panacea Biotec",
    "full_name": "Panacea Biotec Ltd",
    "name_url": "stocks-analysis/panacea-biotec",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "336.25",
    "chg": -17.05,
    "chgp": "-4.83%",
    "dir": -1,
    "prev_price": "353.30",
    "mcapval": "2,133.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 531349,
    "symbol": "PANACEABIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE922B01023",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "1.39 lacs",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/panacea-biotec-622974-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Panacea Biotec Declines 4.96% Amid Mixed Signals and Elevated Valuation Risks",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/panacea-biotec-declines-496-amid-mixed-signals-and-elevated-valuation-risks-4270714",
        "imagepath": "",
        "date": "2026-11-21 16:07:10",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Nov:</strong> Intraday high surge of 7.69% to Rs.380.45 amid gap-up opening</p>\n                    <p><strong>16 Nov:</strong> Mixed quarterly results reveal strong revenue but negative cash flow</p>\n                    <p><strong>17 Nov:</strong> Valuation metrics signal elevated price risk with P/E ratio at 206.6</p>\n                    <p><strong>20 Nov:</strong> Sharp 4.83% drop to Rs.336.25 despite Sensex gains</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.353.80</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">We..."
      },
      {
        "title": "Panacea Biotec Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/panacea-biotec-ltd-is-rated-strong-sell-4270074",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/PanaceaBiotecLt_mojoScore_4270074.png",
        "date": "2026-11-21 10:10:19",
        "description": "Panacea Biotec Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Panacea Biotec Ltd Valuation Shifts Signal Elevated Price Risk Amid Sector Comparisons",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/panacea-biotec-ltd-valuation-shifts-signal-elevated-price-risk-amid-sector-comparisons-4264584",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/PanaceaBiotecLt_valuationdot_4264584.png",
        "date": "2026-11-17 08:01:08",
        "description": "Panacea Biotec Ltd’s valuation metrics have undergone a marked deterioration, with its price-to-earnings (P/E) ratio soaring to 206.6 and price-to-book value (P/BV) rising to 2.58, signalling a shift from risky to very expensive territory. This valuation expansion contrasts sharply with both its historical averages and peer group benchmarks, raising concerns about price attractiveness amid subdued financial performance and negative returns over recent periods."
      },
      {
        "title": "Panacea Biotec Ltd Reports Mixed Quarterly Results Amid Flat Financial Trend",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/panacea-biotec-ltd-reports-mixed-quarterly-results-amid-flat-financial-trend-4264180",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/PanaceaBiotecLt_fintrenddot_4264180.png",
        "date": "2026-11-16 14:00:32",
        "description": "Panacea Biotec Ltd’s latest quarterly results reveal a complex financial picture, with robust revenue growth and margin expansion contrasting sharply against deteriorating cash flow metrics. Despite a strong uptick in net sales and profitability for the quarter ended September 2026, the company’s overall financial trend has shifted from very positive to flat, prompting a downgrade in its Mojo Grade to Strong Sell."
      },
      {
        "title": "Panacea Biotec Ltd Faces Bearish Momentum Amid Technical Downturn",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/panacea-biotec-ltd-faces-bearish-momentum-amid-technical-downturn-4263039",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/PanaceaBiotecLt_technicaldot_4263039.png",
        "date": "2026-11-16 08:02:22",
        "description": "Panacea Biotec Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen a marked shift in its technical momentum, with key indicators signalling a bearish trend. The company’s stock price has declined by 1.83% today, closing at ₹353.80, reflecting growing investor caution amid weakening technical signals and a downgrade in its Mojo Grade to Strong Sell."
      },
      {
        "title": "Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/panacea-biotec-ltd-technical-momentum-shifts-amid-mixed-market-signals-4260000",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/PanaceaBiotecLt_technicaldot_4260000.png",
        "date": "2026-11-13 08:03:11",
        "description": "Panacea Biotec Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend, reflecting a complex interplay of technical indicators. Despite a modest day gain of 1.65%, the stock’s broader technical signals and relative performance against the Sensex suggest cautious investor sentiment amid ongoing volatility in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Panacea Biotec Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/panacea-biotec-ltd-is-rated-strong-sell-4257403",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/PanaceaBiotecLt_mojoScore_4257403.png",
        "date": "2026-11-10 10:10:16",
        "description": "Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 24 August 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the company’s current position as of 10 November 2026, providing investors with the latest insights into its performance and prospects."
      },
      {
        "title": "Panacea Biotec Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/panacea-biotec-ltd-is-rated-strong-sell-4227794",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/PanaceaBiotecLt_mojoScore_4227794.png",
        "date": "2026-10-16 10:10:25",
        "description": "Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 16 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Panacea Biotec Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/panacea-biotec-ltd-is-rated-strong-sell-4214641",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/PanaceaBiotecLt_mojoScore_4214641.png",
        "date": "2026-10-05 10:10:19",
        "description": "Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 97,
    "sid": "622974",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/panacea-biotec-622974"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Nov-2026",
      "details": "Please find attached newspaper copies of the extract of statement of Unaudited Financial Results for the quarter and half year ended September 30 2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half-Year Ended September 30 2026",
      "datetime": "14-Nov-2026",
      "details": "We would like to inform you that the Board of Directors has at its meeting held today i.e. Saturday November 14 2026 inter-alia considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half-year ended September 30 2026.",
      "source": "BSE"
    },
    {
      "caption": "Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half-Year Ended September 30 2026",
      "datetime": "14-Nov-2026",
      "details": "Please find attached Unaudited Financial Results for quarter and half year ended September 30 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Panacea Biotec Ltd has declared <strong>75%</strong> dividend, ex-date: 19 Sep 11",
          "dt": "2011-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

16-Nov-2026 | Source : BSE

Please find attached newspaper copies of the extract of statement of Unaudited Financial Results for the quarter and half year ended September 30 2026.

Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half-Year Ended September 30 2026

14-Nov-2026 | Source : BSE

We would like to inform you that the Board of Directors has at its meeting held today i.e. Saturday November 14 2026 inter-alia considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half-year ended September 30 2026.

Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half-Year Ended September 30 2026

14-Nov-2026 | Source : BSE

Please find attached Unaudited Financial Results for quarter and half year ended September 30 2026

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Panacea Biotec Ltd has declared 75% dividend, ex-date: 19 Sep 11

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available